Congress Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Congress Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.62M	Buy	223,883 +43,435	+24%	+$710K	0.02%	288
2026 Q2	$3.51M	Buy	180,448 +1,893	+1%	+$34.3K	0.02%	264
2026 Q1	$3.33M	Buy	178,555 +107,459	+151%	+$1.78M	0.02%	271
2025 Q4	$937K	Sell	71,096 -2,269	-3%	-$26.8K	0.01%	315
2025 Q3	$526K	Buy	73,365 +514	+0.7%	+$26.8K	﹤0.01%	351
2025 Q2	$3.44M	Buy	72,851 +121	+0.2%	+$4.93K	0.02%	250
2025 Q1	$2.84M	Sell	72,730 -263	-0.4%	-$11.3K	0.02%	255
2024 Q4	$3.95M	Buy	72,993 +6,352	+10%	+$324K	0.03%	248
2024 Q3	$3.36M	Buy	+66,641	New	+$3.12M	0.02%	252

Other funds holding MLTX

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Congress Asset Management's MLTX Position: Q3 2026 in Review

Congress Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 24% in Q3 2026, buying an estimated $710K and bringing the position to 223,883 shares worth $2.62M. The position accounts for 0.02% of the portfolio, ranked #288.

Congress Asset Management first reported a position in MLTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.95M in Q4 2024. 14 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Congress Asset Management held 223,883 shares of MoonLake Immunotherapeutics worth $2.62M as of Q3 2026.
Congress Asset Management bought 43,435 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $710K.
MoonLake Immunotherapeutics made up 0.02% of Congress Asset Management's portfolio in Q3 2026, its #288 holding.
Congress Asset Management first reported a position in MoonLake Immunotherapeutics in Q3 2024 and has held it in 9 quarters since.
Congress Asset Management's MoonLake Immunotherapeutics position peaked at $3.95M in Q4 2024.
14 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.